Wilson Disease
Conditions
Interventions
Gandouling intervention group:The intervention group of Gandouling capsules on the basis of the HLD case-control group, liver douling capsules(0.3g/capsule, prepared by the Preparation Center of the F
control group:Conventional copper removal and hepatoprotective therapy
Sponsors
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
15 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Complies with the diagnosis of hepatolenticular degeneration in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Hepatolenticular Degeneration 2021; 2. Age range from 15 to 55 years old; 3. Avoid taking other traditional Chinese medicine or traditional Chinese patent medicines and simple preparations during the study period; 3. The patient or legal representative shall give informed consent and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Liver cirrhosis in the decompensated stage, manifested by portal hypertension, ascites, splenomegaly (WBC<3.0×10 9/L, PT<50×10 9), esophageal varices, gastrointestinal hemorrhage, moderate-to-severe anemia, or hepatic encephalopathy; 2. moderate-to-severe depression, recent suicidal thoughts or behavior, or severe psychiatric symptoms; 3. a history of severe seizures; 4. taking other Chinese medicines or proprietary Chinese medicines during the study period 5. patients who are unable to cooperate with the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Copper;Ceruloplasmin;CoPPer oxidase;24-hour urine copper; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine;Liver function; | — |
Countries
China
Contacts
Public ContactCao Shijian
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Outcome results
None listed